4D Molecular Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for 4D Molecular Therapeutics, Inc. (FDMT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-160.87-100.84-107.49-71.32-56.69
Depreciation & Amortization6.715.754.943.021.44
Stock Based Compensation26.1219.7517.2113.805.03
Change in Working Capital0.542.24-1.01-15.53-0.71
Change in Accounts Receivable0.000.000.051.44-0.51
Change in Accounts Payable0.870.90-1.642.290.04
Change in Other Working Capital-0.330.453.39-4.54-0.59
Other Operating Activities-7.0817.0616.880.090.02
Net Cash from Operating Activities-134.59-75.79-86.69-69.13-50.91
Investing Activities
Capital Expenditures-3.792.7711.54-9.11-1.00
Purchases of Investments-467.65118.49-5.51-168.570.00
Sales/Maturities of Investments169.00118.49-5.515.000.00
Net Cash from Investing Activities-302.44115.72-17.05-172.68-1.00
Financing Activities
Common Stock Issued331.417.312.73114.30206.52
Other Financing Activities5.841.180.820.00-3.14
Net Cash from Financing Activities337.25156.833.09118.09278.98
Summary
Net Change in Cash-99.77196.76-100.65-123.73227.07
Cash at Beginning of Period249.1152.35153.00276.730.00
Cash at End of Period149.3448.4152.35153.000.00
Free Cash Flow-138.37-78.56-98.22-78.24-51.91